['gout']
['rdea3170 15 mg', 'rdea3170 10 mg', 'rdea3170 2.5', 'rdea3170 5 mg', 'febuxostat 40 mg', 'febuxostat 80 mg']

        Inclusion Criteria:

          -  Able to understand the study procedures and the risks involved and is willing to
             provide written informed consent before the first study-related activity.

          -  Meets one or more criteria for the diagnosis of gout as per the American Rheumatism
             Association Criteria for the Classification of Acute Arthritis of Primary Gout.

          -  Body weight ≥ 50 kg (110 lbs) and a body mass index ≥ 18 and ≤ 45 kg/m2.

          -  Screening serum urate level ≥ 8 mg/dL.

          -  Free of any clinically significant disease or medical condition, per the
             Investigator's judgment.

        Exclusion Criteria:

          -  Unable to take colchicine for gout flare prophylaxis.

          -  History or suspicion of kidney stones.

          -  Any gastrointestinal disorder that affects motility and/or absorption.

          -  Unstable angina, New York Heart Association class III or IV heart failure, ischemic
             heart disease, stroke, or deep venous thrombosis within 12 months prior to Day 1; or
             subject is currently receiving anticoagulants.

          -  Screening laboratory parameters that are outside the normal limits and are considered
             clinically significant by the Investigator.

          -  Estimated creatinine clearance < 60 mL/min calculated by the Cockcroft-Gault formula
             using ideal body weight during the Screening period.

          -  Taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked transporter-2
             inhibitors; chronic and stable doses are permitted if doses are stable for at least 14
             days prior to study medication dosing.

          -  Unable or unwilling to comply with the study requirements or has a situation or
             condition that, in the opinion of the Investigator, may interfere with participation
             in the study.
      